Medi-Tech Insights Get in touch

Global Obesity Drugs Market Size, Share, Growth & Trends Report Segmented by Drug Type (Prescription, OTC), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies/E-commerce) & Regional Forecast to 2031

Request Quote Download FREE Sample
Single User

Table of Contents

  1. Introduction
    • Introduction
    • Market Scope
      • Market Definition
      • Segments Covered
      • Regional Segmentation
    • Research Timeframe
    • Currency Considered
    • Study Limitations
    • Stakeholders
    • List of Abbreviations
    • Key Conferences and Events (2026-2027)
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Market Estimation
      • Bottom-Up Approach
      • Top-Down Approach
    • Market Forecasting
  3. Executive Summary
    • Obesity Drugs Market Snapshot (2026-2031)
    • Segment Overview
    • Regional Snapshot
    • Competitive Insights
  4. Marketion of GLP-1 and multi-agonist drugs
  5. Increased payer and government focus on obesity as a chronic disease
  6. Growing investments from major pharma companies in metabolic drug pipelines
  7. Rising demand for pharmacologic therapy due to limitations of lifestyle interventions
  8. Restraints
    • High cost of branded obesity drugs and limited insurance reimbursement in many countries
    • Side-effects (GI effects, long-term safety data gaps) impacting adherence
    • Supply constraints and manufacturing capacity limitations for GLP-1 class drugs
  9. Opportunities
    • Expansion into oral GLP-1 and multi-agonist formulations offering higher convenience
    • Development of combination therapies targeting weight loss and metabolic outcomes
    • Growth of virtual obesity management platforms integrating drugs with monitoring and coaching
  10. Key Market Trends
    • Rapid pipeline shift towardrugs (GLP-1/GIP, GLP-1/GCGR) showing superior weight loss
    • Integration of obesity drug therapy with digital health ecosystems and remote patient monitoring
  11. Unmet Market Needs
  12. Industry Speaks
  13. Pipeline Analysis
    14. "5">
  14. Global Obesity Drugs Market Size & Forecast (2024-2031), By Drug Type, USD Billion
    • Introduction
    • Prescription Drugs
    • OTC Drugs
  15. Global Obesity Drugs Market Size & Forecast (2024-2031), By Distribution Channel, USD Billion
    • Introduction
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies/E-commerce
  16. Global Obesity Drugs Market Size & Forecast (2024-2031), By Region, USD Billion
    • Introduction
    • North America Obesity Drugs Market Size & Forecast (2024-2031), By Country, USD Billion
      • US
        • Market Size & Forecast, By Drug Type, (USD Billion)
        • Market Size & Forecast, By Distribution Channel, (USD Billion)
      • Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
  17. Europe Obesity Drugs Market Size & Forecast (2024-2031), By Country, USD Billion
    • UK
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • Germany
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • France
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • Italy
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • Sution Channel, (USD Billion)
  18. Rest of Europe
    • Market Size & Forecast, By Drug Type, (USD Billion)
    • Market Size & Forecast, By Distribution Channel, (USD Billion)
  19. Asia Pacific (APAC) Obesity Drugs Market Size & Forecast (2024-2031), By Country, USD Billion
    • China
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • Japan
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • India
      • Market Size & Forecast, By Drug Type, (USD Billion)
      • Market Size & Forecast, By Distribution Channel, (USD Billion)
    • Rest of Asia Pacific
      • MarkBillion)
  20. Latin America (LATAM) Obesity Drugs Market Size & Forecast (2024-2031), USD Billion
    • Market Size & Forecast, By Drug Type, (USD Billion)
    • Market Size & Forecast, By Distribution Channel, (USD Billion)
  21. Middle East & Africa (MEA) Obesity Drugs Market Size & Forecast (2024-2031), USD Billion
    • Market Size & Forecast, By Drug Type, (USD Billion)
    • Market Size & Forecast, By Distribution Channel, (USD Billion)
  22. Competitive Landscape
    • Key Players and their Competitive Positioning
      • Key Player Comparison
      • Segment-wise Player Mapping
      • Market Share Analysis (2025)
      • Company Categorization Matrix
        • Dominants/Leaders
        • New Entrants
        • Emerging Players
        • Innovative Players
    • Key Strategies Assessment, By Player (2023-2025)
      • New Product Launch/Approval
      • Partnerships, Agreements, & Collaborations
      • Mergers & Acquisitions
      • Geographic Expansion
  1. Company Profiles*

(Business Overview, Financial Performance**, Products Offered, Recent Developments)

    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Altimmune
    • Amgen Inc.
    • Boehringer Ingelheim
    • Innovent Biologics, Inc.
    • AstraZeneca plc
    • Pfizer Inc.
    • VIVUS LLC
    • GlaxoSmithKline PLC
    • Other Prominent Players

Related Reports

View All Research Reports